Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Core Insights - Nurix Therapeutics has announced an exclusive licensing agreement with Sanofi for a previously undruggable transcription factor targeting autoimmune diseases, which is a central regulator of inflammation [1][2] - The collaboration has generated a total of $105 million in payments to Nurix, with the potential for an additional$465 million in development, regulatory, and commercial milestones, along with future royalties [1][2] - Nurix's DEL-AI drug discovery platform has successfully identified novel agents for this target, enhancing the drug discovery pipeline for autoimmune diseases [2] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [3][4] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), as well as multiple preclinical programs [3][4] - Nurix has received a total of $460 million from various partners, including the$105 million from the Sanofi collaboration, which is crucial for expanding its drug discovery pipeline [2][3]